Literature DB >> 27155373

Could drugs inhibiting the mevalonate pathway also target cancer stem cells?

Wirginia Likus1, Krzysztof Siemianowicz2, Konrad Bieńk3, Małgorzata Pakuła4, Himani Pathak5, Chhanda Dutta6, Qiong Wang7, Shahla Shojaei8, Yehuda G Assaraf9, Saeid Ghavami10, Artur Cieślar-Pobuda11, Marek J Łos12.   

Abstract

Understanding the connection between metabolic pathways and cancer is very important for the development of new therapeutic approaches based on regulatory enzymes in pathways associated with tumorigenesis. The mevalonate cascade and its rate-liming enzyme HMG CoA-reductase has recently drawn the attention of cancer researchers because strong evidences arising mostly from epidemiologic studies, show that it could promote transformation. Hence, these studies pinpoint HMG CoA-reductase as a candidate proto-oncogene. Several recent epidemiological studies, in different populations, have proven that statins are beneficial for the treatment-outcome of various cancers, and may improve common cancer therapy strategies involving alkylating agents, and antimetabolites. Cancer stem cells/cancer initiating cells (CSC) are key to cancer progression and metastasis. Therefore, in the current review we address the different effects of statins on cancer stem cells. The mevalonate cascade is among the most pleiotropic, and highly interconnected signaling pathways. Through G-protein-coupled receptors (GRCP), it integrates extra-, and intracellular signals. The mevalonate pathway is implicated in cell stemness, cell proliferation, and organ size regulation through the Hippo pathway (e.g. Yap/Taz signaling axis). This pathway is a prime preventive target through the administration of statins for the prophylaxis of obesity-related cardiovascular diseases. Its prominent role in regulation of cell growth and stemness also invokes its role in cancer development and progression. The mevalonate pathway affects cancer metastasis in several ways by: (i) affecting epithelial-to-mesenchymal transition (EMT), (ii) affecting remodeling of the cytoskeleton as well as cell motility, (iii) affecting cell polarity (non-canonical Wnt/planar pathway), and (iv) modulation of mesenchymal-to-epithelial transition (MET). Herein we provide an overview of the mevalonate signaling network. We then briefly highlight diverse functions of various elements of this mevalonate pathway. We further discuss in detail the role of elements of the mevalonate cascade in stemness, carcinogenesis, cancer progression, metastasis and maintenance of cancer stem cells.
Copyright © 2016 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Cancer stem-like cells; Mevalonate cascade; Ras; Rho; Statins; Stemness; Yap

Mesh:

Substances:

Year:  2016        PMID: 27155373     DOI: 10.1016/j.drup.2016.02.001

Source DB:  PubMed          Journal:  Drug Resist Updat        ISSN: 1368-7646            Impact factor:   18.500


  21 in total

Review 1.  The balance of protein farnesylation and geranylgeranylation during the progression of nonalcoholic fatty liver disease.

Authors:  Yue Zhao; Tian-Yu Wu; Meng-Fei Zhao; Chao-Jun Li
Journal:  J Biol Chem       Date:  2020-03-05       Impact factor: 5.157

2.  In Vitro Validation of the Hippo Pathway as a Pharmacological Target for Canine Mammary Gland Tumors.

Authors:  Samantha Guillemette; Charlène Rico; Philippe Godin; Derek Boerboom; Marilène Paquet
Journal:  J Mammary Gland Biol Neoplasia       Date:  2017-08-18       Impact factor: 2.673

3.  The mevalonate pathway promotes the metastasis of osteosarcoma by regulating YAP1 activity via RhoA.

Authors:  Xing Du; Yunsheng Ou; Muzi Zhang; Kai Li; Wei Huang; Dianming Jiang
Journal:  Genes Dis       Date:  2020-11-21

Review 4.  The interplay between mutant p53 and the mevalonate pathway.

Authors:  Alejandro Parrales; Elizabeth Thoenen; Tomoo Iwakuma
Journal:  Cell Death Differ       Date:  2017-12-13       Impact factor: 15.828

5.  Structure and properties of slow-resorbing nanofibers obtained by (co-axial) electrospinning as tissue scaffolds in regenerative medicine.

Authors:  Andrzej Hudecki; Joanna Gola; Saeid Ghavami; Magdalena Skonieczna; Jarosław Markowski; Wirginia Likus; Magdalena Lewandowska; Wojciech Maziarz; Marek J Los
Journal:  PeerJ       Date:  2017-12-18       Impact factor: 2.984

6.  Genome scale metabolic models as tools for drug design and personalized medicine.

Authors:  Vytautas Raškevičius; Valeryia Mikalayeva; Ieva Antanavičiūtė; Ieva Ceslevičienė; Vytenis Arvydas Skeberdis; Visvaldas Kairys; Sergio Bordel
Journal:  PLoS One       Date:  2018-01-05       Impact factor: 3.240

Review 7.  New frontiers in the treatment of colorectal cancer: Autophagy and the unfolded protein response as promising targets.

Authors:  Pooneh Mokarram; Mohammed Albokashy; Maryam Zarghooni; Mohammad Amin Moosavi; Zahra Sepehri; Qi Min Chen; Andrzej Hudecki; Aliyeh Sargazi; Javad Alizadeh; Adel Rezaei Moghadam; Mohammad Hashemi; Hesam Movassagh; Thomas Klonisch; Ali Akbar Owji; Marek J Łos; Saeid Ghavami
Journal:  Autophagy       Date:  2017-02-23       Impact factor: 16.016

8.  Mevalonate Cascade Inhibition by Simvastatin Induces the Intrinsic Apoptosis Pathway via Depletion of Isoprenoids in Tumor Cells.

Authors:  Javad Alizadeh; Amir A Zeki; Nima Mirzaei; Sandipan Tewary; Adel Rezaei Moghadam; Aleksandra Glogowska; Pandian Nagakannan; Eftekhar Eftekharpour; Emilia Wiechec; Joseph W Gordon; Fred Y Xu; Jared T Field; Ken Y Yoneda; Nicholas J Kenyon; Mohammad Hashemi; Grant M Hatch; Sabine Hombach-Klonisch; Thomas Klonisch; Saeid Ghavami
Journal:  Sci Rep       Date:  2017-03-27       Impact factor: 4.379

9.  Relationship of SNP rs2645429 in Farnesyl-Diphosphate Farnesyltransferase 1 Gene Promoter with Susceptibility to Lung Cancer.

Authors:  Mehdi Dehghani; Zahra Samani; Hassan Abidi; Leila Manzouri; Reza Mahmoudi; Saeed Hosseini Teshnizi; Mohsen Nikseresht
Journal:  Int J Genomics       Date:  2018-03-22       Impact factor: 2.326

10.  Overexpression of geranylgeranyl diphosphate synthase contributes to tumour metastasis and correlates with poor prognosis of lung adenocarcinoma.

Authors:  Xiaoxia Wang; Wujian Xu; Ping Zhan; Tianxiang Xu; Jiajia Jin; Yingying Miu; Zejun Zhou; Qingqing Zhu; Bing Wan; Guangmin Xi; Liang Ye; Yafang Liu; Jianwei Gao; Huijuan Li; Tangfeng Lv; Yong Song
Journal:  J Cell Mol Med       Date:  2018-01-29       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.